Lakefront Biotherapeutics NV (LKFT)
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Lakefront Biotherapeutics N.V.
NASDAQ:LKFTHealthcare · Biotechnology
-0.15%$32.28
AH$32.28+0.00%vs close
Mkt Cap$2.13B
Float65.9M
O/S65.9M
Vol
$ Vol
RVOL
Inst Own48.7%
SI2.1%
Earnings
Dilution
Financials Summary
Revenue$1.24B
Net Income$358.49M
Total Assets$3.81B
Free Cash Flow-$303.11M
Debt & Equity
Debt 0%
Equity 100%
Total Debt$7.73M
Total Equity$3.62B
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in LKFT's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$3.81B
Liabilities$190.65M
Accounts Receivable$59.44M
Accounts Payable$36.44M
Inventory$25.13M
PP&E (Net)$90.12M
Goodwill$0
Intangible Assets$947K
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Revenue | $1.24B | $307.96M | $267.82M | $269.52M | $261.85M |
| YoY Growth | 303.5% | 15.0% | -0.6% | 2.9% | - |
| Cost of Revenue | $33.22M | $38.95M | $0 | $0 | $358.07M |
| Gross Profit | $1.21B | $269.01M | $267.82M | $269.52M | -$96.21M |
| Gross Margin | 97.3% | 87.4% | 100.0% | 100.0% | -36.7% |
| Research and Development | $513.27M | $374.77M | $269.57M | $301.42M | $358.07M |
| Selling, General, and Administrative | $125.08M | $108.23M | $105.3M | $115.42M | $146.93M |
| Other | $10.88M | -$3.59M | -$8.44M | -$895K | -$409.54M |
| Total Operating Expenses | $649.23M | $479.42M | $366.43M | $415.94M | $95.46M |
| Operating Income (EBIT) | $560.15M | -$210.41M | -$98.61M | -$146.42M | -$191.68M |
| Operating Margin | 45.1% | -68.3% | -36.8% | -54.3% | -73.2% |
| Interest Expense | $2.48M | $1.02M | $1.98M | $10.23M | $9.75M |
| Interest Income | $51.77M | $100.29M | $88.94M | $20.21M | $0 |
| Other Income (Expense) | -$224.02M | $206.96M | $104.89M | $67.26M | $58.28M |
| Income Before Tax (EBT) | $336.13M | -$3.45M | $6.28M | -$79.15M | -$133.4M |
| Income Tax Expense | -$20.8M | -$2.01M | $10.74M | $639K | $1.55M |
| Net Income | $358.49M | $82.76M | $236.51M | -$243.54M | -$115.33M |
| Net Income Margin | 28.9% | 26.9% | 88.3% | -90.4% | -44.0% |
| Supplementary Data | |||||
| EPS | 4.87 | 1.12 | 3.21 | -3.32 | -1.84 |
| Diluted EPS | 4.87 | 1.12 | 3.21 | -3.32 | -1.84 |
| Weighted Average OS | 65.90M | 66.14M | 65.88M | 65.66M | 55.98M |
| EBITDA | $401.03M | $48.4M | $57.02M | $4.33M | -$182.39M |
| EBITDA Margin | 32.3% | 15.7% | 21.3% | 1.6% | -69.7% |
Balance Sheet
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-12-31 |
| Assets | |
| Current Assets | |
| Cash and Cash Equivalents | $98.17M |
| Short-Term Investments | $3.25B |
| Cash and Short-Term Investments | $3.35B |
| Accounts Receivable | $59.44M |
| Inventory | $25.13M |
| Other Current Assets | $6.27M |
| Total Current Assets | $3.44B |
| Long-Term Assets | |
| Property, Plant & Equipment Net | $90.12M |
| Goodwill | $0 |
| Intangible Assets | $947K |
| Long-Term Investments | $52.3M |
| Deferred Tax Assets | $218K |
| Other Long-Term Assets | $221.82M |
| Total Long-Term Assets | $365.39M |
| Other Assets | $0 |
| Total Assets | $3.81B |
| Liabilities | |
| Current Liabilities | |
| Accounts Payable | $36.44M |
| Short-Term Debt | $0 |
| Current Income Tax Payable | $1.07M |
| Current Unearned Revenue | $36K |
| Other Current Liabilities | $131.28M |
| Total Current Liabilities | $170.78M |
| Long-Term Liabilities | |
| Long-Term Debt | $0 |
| Long-Term Unearned Revenue | $0 |
| Long-Term Deferred Tax Liabilities | $0 |
| Other Long-Term Liabilities | $14.08M |
| Total Long-Term Liabilities | $19.87M |
| Other Liabilities | $0 |
| Total Liabilities | $190.65M |
| Stockholders' Equity | |
| Preferred Stock | $0 |
| Common Stock | $328.39M |
| Retained Earnings | $235.26M |
| Comprehensive Income & Other | -$6.3M |
| Other Stockholders' Equity | $3.05B |
| Total Equity | $3.62B |
| Minority Interest | $0 |
| Total Liabilities and Equity | $3.81B |
| Supplementary Data | |
| Total Debt | $7.73M |
| Net Debt | -$90.44M |
Cash Flow Statement
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-12-31 |
| Operating Activities | |
| Net Income | $358.49M |
| Depreciation & Amortization | $62.42M |
| Deferred Income Tax | -$20.26M |
| Stock-Based Compensation | $26.81M |
| Changes in Working Capital: | |
| Accounts Receivable | $96.74M |
| Inventory | $32.23M |
| Accounts Payable | $0 |
| Other Working Capital | -$1.11B |
| Total Working Capital Change | -$979.3M |
| Other Non-Cash Items | $264.21M |
| Net Cash from Operating | -$287.63M |
| Investing Activities | |
| Capital Expenditures | -$15.31M |
| Acquisitions | $21.71M |
| Purchases of Investments | -$3.87B |
| Sales of Investments | $4.14B |
| Other Investing Activities | $45.53M |
| Net Cash from Investing | $322.66M |
| Financing Activities | |
| Debt Repaid | $3.66M |
| Common Stock Issuance | $0 |
| Common Stock Repurchases | $0 |
| Dividends Paid | $0 |
| Other Financing Activities | $0 |
| Net Cash from Financing | -$3.66M |
| Forex Effect | -$4.98M |
| Net Change in Cash | $26.4M |
| Supplementary Data | |
| Operating Cash Flow | -$287.63M |
| Capital Expenditure | -$15.48M |
| Free Cash Flow | -$303.11M |
| Cash at Beginning | $71.77M |
| Cash at End | $98.17M |